Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 3 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 28, 2015 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Pfizer
- Interventions being studied
- Drug: axitinib; Drug: axitinib; Drug: chemotherapy; Drug: axitinib; Drug: chemotherapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Histologically or cytologically confirmed diagnosis of adeno-, large cell or bronchioalveolar non-small cell lung cancer
- Cytologic specimens for diagnosis or for cell type classification must have been obtained from bronchial brushings or washings or from needle aspiration of a defined lesion. Sputum cytology alone will not be acceptable for diagnosis or for cell type classification.
- Patients with mixed NSCLC with predominantly squamous cell carcinoma should be classified as squamous and thus do not qualify for this study.
- Stage IIIB with malignant effusion (with cytologic confirmation of malignant pleural or pericardial effusion), Stage IV, or recurrent disease after definitive loco-regional therapy.
- Candidate for primary treatment with cisplatin and pemetrexed
- Any histological/cytological evidence of predominantly squamous NSCLC.
- Small cell or carcinoid lung cancer patients are also ineligible.
- NSCLC that cannot be classified as one of the eligible histologies (adenocarcinoma, large cell or bronchioalveolar).
- Prior systemic therapy for Stage IIIB (with malignant effusion), Stage IV, or recurrent NSCLC. (Prior treatment with systemic therapy as adjuvant chemotherapy or in conjunction with radiotherapy for Stage II or III NSCLC is permitted if the last dose of chemotherapy was completed 12 months or more prior to randomization).
- Prior treatment with a VEGF or VEGFR inhibitor.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Pfizer Investigational SiteHuntsville, Alabama
- Pfizer Investigational SiteAtlanta, Georgia
- Pfizer Investigational SiteDecatur, Georgia
- Pfizer Investigational SiteMacon, Georgia
- Pfizer Investigational SiteMarietta, Georgia
- Pfizer Investigational SiteSandy Springs, Georgia
- Pfizer Investigational SiteBloomington, Illinois
- Pfizer Investigational SitePeoria, Illinois
- Pfizer Investigational SiteHershey, Pennsylvania
- Pfizer Investigational SiteWest Reading, Pennsylvania
- Pfizer Investigational SiteEast Providence, Rhode Island
- Pfizer Investigational SiteEast Providence, Rhode Island
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 28, 2015. Always confirm current availability with the study team.